Advertising Opportunities

Jeff Hennessy, Jr.
President, HMP Omnimedia
jhennessyjr@hmpglobal.com

Tony Deimler
Associate Director
tdeimler @hmpglobal.com

Joe Sylo
Senior National Accounts Manager
jsylo@hmpglobal.com

Jennifer Guido
National Accounts Manager
jguido@hmpglobal.com

Logan Brenker
National Accounts Manager
lbrenker@hmpglobal.com

May 2023

Current Issue

May 2023

Volume 63

Issue 5

Research Summaries

Research Summary

Blood Test Detects Residual Disease For Adults With AML in Remission Prior to Bone Marrow Transplant

05/31/2023

Anthony Calabro, MA

Researchers performed a retrospective observational study to determine whether DNA sequencing can detect residual disease in adults with acute myeloid leukemia (AML) in first remission.

05/31/2023

Research Summary

High Long-term Survivability, Patient Satisfaction Following Robotic-arm—assisted Medial UKA

05/31/2023

Anthony Calabro, MA

The authors set out to determine implant survivorship and patient satisfaction of robotic-arm—assisted unicompartmental knee arthroplasty at 10-years follow-up.

05/31/2023

research summary

research summary

Opioids Are the Most Frequent Substance in Pediatric Poisoning Fatalities

05/30/2023

Leigh Precopio

To guide prevention efforts for fatal poisonings in pediatric patients, the authors of a recent study examined characteristics of death from poisoning in young children within the United States.

05/30/2023

Conference Coverage

Conference Coverage

Making the Most of Your Conversations About Advance Care Planning

05/30/2023

Anthony Calabro, MA

In their presentation at the 48th ONS Congress, in San Antonio, Texas, Denise Nicholson BSN, RN and Colleen Nevins DNP, RN, CNE describe the best practices for advance care planning conversations and review...

05/30/2023

FDA Alert

FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose

05/27/2023

Jessica Ganga

The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.

05/27/2023

Poll

What do you observe as the main reason for nonadherence to urate-lowering therapy among your patients with gout?

Patients tend to feel better between flares.

Patients do not want to begin treatment with another medication.

Patients can be discouraged from continuing treatment if they experience flares at the initiation of urate-lowering therapy.

Submit Answer